Table 1.

PI3K inhibitors preclinically evaluated in acute lymphoblastic leukemia (ALL).

Therapeutic Drug	Target (s)	Preclinical Model	Reference
Idelalisib (CAL101)	PI3Kδ inhibitor	B-ALL	[16,52,62,63,64,65]
PI3KD-IN-015	PI3Kδ inhibitor	B-ALL	[70]
Duvelisib (ABBV-954, INK-1197, IPI-145)	PI3Kδ/PI3Kγ inhibitor	B-ALL	[72]
SF2535	PI3Kδ/BRD4 inhibitor	B-ALL	[75]
PKI-587	PI3K/mTOR inhibitor	T-ALL	[76]
Dactolisib (BEZ235)	PI3K/mTOR inhibitor	B-ALL	[77]
ZSTK-474	PI3K pan- inhibitor	T-ALL	[78,79]